ReviewImmunology2012
Interleukin-23: as a drug target for autoimmune inflammatory diseases.
Review in Immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 155 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
155 citing papers in PubMed, 1 synthesis or guideline pooled it, 330 citations in OpenAlex.
- Anti-IL-17 therapy in treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials.Rheumatology international · 2016Pooled it
- Pseudomonas aeruginosa induces the generation of pathogenic IFNγNature microbiology · 2026Article
- Article
- Circulating miR-221/222 and Serum IL-23 in Treatment-Naïve Multiple Sclerosis: A Case-Control Study.Medicina (Kaunas, Lithuania) · 2026Observational
- In Silico Identification and Structural Characterization of High-Risk Missense SNVs in the HumanGenes · 2026Article
- Safety and immunogenicity of a tri-antigen vaccine targeting IGFBP-2, HER2, and IGF-IR in participants with non-metastatic breast cancer.Journal for immunotherapy of cancer · 2026Article
- Progress in Designing Cytokine Antagonist Antibodies for Cancer Therapy.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Wogonin attenuates psoriasis through anti-inflammatory effects by inhibiting reactive oxygen species production and the AKT/NF-κB signaling pathway.Scientific reports · 2026Article
- Genetic inhibition of IL-12β suppresses systolic overload-induced cardiac oxidative stress, inflammation, and heart failure development.Redox biology · 2026Article
- ReverseGWAS identifies combined phenotypes associated with a genotype in GWA studies.Bioinformatics (Oxford, England) · 2026Article
- Structure-based screening of small-molecule interleukin-23 inhibitors inspired by monoclonal antibody interactions.Molecular diversity · 2026Article
- Interleukin Signatures as Prognostic Biomarkers in Ulcerative Colitis: From Immune Pathways to Clinical Prediction.Current issues in molecular biology · 2026Review
- Effects of tildrakizumab on circulating T cells in autoreactive psoriatic patients.Frontiers in immunology · 2026Article
- Immunological Diagnosis and Treatments of Periodontitis in Patients with Type 2 Diabetes Mellitus.Advances in experimental medicine and biology · 2026Review
- Sustained in situ protein production and release in the mammalian gut by an engineered bacteriophage.Nature biotechnology · 2026Article
- Overrepresentation of Germline Immune-Related Gene Variants in Patients with Acquired Bone Marrow Failure.Journal of clinical immunology · 2025Article
- The Potential Role of Microalgal Antioxidant Molecules on the Microbiota-Gut Axis in Inflammatory Bowel Diseases.Biomolecules · 2025Review
- eNAMPT/TLR4 signaling drives PAH cellular phenotypic switching and lung vascular remodeling.Cell communication and signaling : CCS · 2025Article
- The invisible agitators: exploring the viral interplay in psoriatic immune dysregulation.Immunologic research · 2025Review
- Genetic inhibition of IL-12β suppresses systolic overload-induced cardiac inflammation and heart failure development.bioRxiv : the preprint server for biology · 2025Article
95 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin-23 (IL-23) is a member of the IL-12 family of cytokines with pro-inflammatory properties. Its ability to potently enhance the expansion of T helper type 17 (Th17) cells indicates the responsibility for many of the inflammatory autoimmune responses. Emerging data demonstrate that IL-23 is a key participant in central regulation of the cellular mechanisms involved in inflammation. Both IL-23 and IL-17 form a new axis through Th17 cells, which has evolved in response to human diseases associated with immunoactivation and immunopathogeny, including bacterial or viral infections and chronic inflammation. Targeting of IL-23 or the IL-23 receptor or IL-23 axis is a potential therapeutic approach for autoimmune diseases including psoriasis, inflammatory bowel disease, rheumatoid arthritis and multiple sclerosis. The current review focuses on the immunobiology of IL-23 and summarizes the most recent findings on the role of IL-23 in the pre-clinical and ongoing clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.